GDF11 Flips Tumor-Protecting Immune Cells Into Cancer Fighters

The tumor microenvironment (TME) is a critical determinant of cancer progression, and tumor-associated macrophages (TAMs) polarized to an M2-like phenotype are among its most potent enablers. These cells promote angiogenesis, tissue remodeling, and broad immunosuppression while relying on aerobic glycolysis and lipid accumulation rather than robust oxidative phosphorylation. Reversing this dysfunctional metabolic identity has long been a therapeutic goal, but conventional approaches rarely address the metabolic programming that sustains M2 identity at its core.

This editorial comments on a study by Escobedo-Calvario et al., published in the World Journal of Gastroenterology, which introduces GDF11 — a member of the TGF-β superfamily — as a potent immunometabolic modulator capable of reprogramming M2-like macrophages in the hepatocellular carcinoma (HCC) context. GDF11 treatment initiates reprogramming through canonical Smad2/3 signaling, the same pathway implicated in anti-hypertrophic effects in cardiomyocytes and anti-differentiation effects in pre-adipocytes, now shown to drive macrophage re-education in the TME.

At the phenotypic level, GDF11 caused dramatic downregulation of CD206 (the mannose receptor), the defining M2 surface marker, signaling decisive de-polarization away from the pro-tumor state. Metabolically, GDF11 significantly increased the oxygen consumption rate — a proxy for restored mitochondrial oxidative phosphorylation — while simultaneously decreasing the extracellular acidification rate, reflecting suppressed glycolytic flux. Total cellular cholesterol content fell substantially, disrupting the lipid-rich environment that sustains M2 maintenance in the TME. Enhanced β-oxidation was also observed, enabling clearance of accumulated lipids and completing a comprehensive bioenergetic overhaul.

A controlled surge in reactive oxygen species (ROS) production accompanied these metabolic changes, functionally arming the re-educated macrophage with microbicidal and pro-inflammatory capacity characteristic of classically activated M1 macrophages. The secretome shifted profoundly: pro-tumor and angiogenic factors including IL-6, ENA-78 (CXCL5), angiogenin, and VEGF were significantly reduced, while anti-tumor mediators IL-1β and TNF-α were markedly elevated. Chemokines MCP-1, MCP-2, MCP-3, CCL2, and RANTES also increased, suggesting enhanced recruitment of anti-tumor immune effectors such as T cells.

Critically, conditioned media from GDF11-treated macrophages effectively suppressed HCC cell proliferation and migration, demonstrating that the secretome shift translates into functional tumor suppression. The authors note that GDF11 appears to create a hybrid re-educated phenotype rather than a classical M1 state, as canonical M1 surface markers like CD80 or CD86 were not reported to increase. Importantly, GDF11 is described as non-cytotoxic, distinguishing it from conventional chemotherapy approaches.

The authors acknowledge important caveats: findings are primarily from in vitro HCC models, and GDF11's effects are context-dependent — in non-oncological settings like myocardial infarction, GDF11 has been shown to promote M2-like repair phenotypes. Broader validation across in vivo models of pancreatic, ovarian, and lung cancers is needed before clinical translation. Future research should map specific metabolic checkpoints regulated by GDF11, including PFKFB3, AMPK, and PPARγ pathways, and explore combination strategies with PD-1/PD-L1 checkpoint blockade to overcome TAM-driven immune exclusion.